Concepedia

Author

Wildon Farwell

Biogen (United States)ORCID

Also Known As

W Farwell, W. Farwell, W. R. Farwell, Wildon Farwell, Wildon R Farwell, Wildon R. Farwell

115

Publications

9.8K

Citations

32

H-Index

78

Concepts

All Affiliations

Biogen (United States)Harvard UniversityVA Boston Healthcare SystemBrigham and Women's HospitalColumbia University Irving Medical Center
WF

About

Wildon Farwell is an author at Biogen (United States) specializing in medicine, pediatrics, and orthopaedics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

16

1.6K

2

Public Health

6

6

542

3

Health Sciences

4

4

1K

4

Arts

1

1

893

5

Child Development

1

1

38

Wildon Farwell

×

47

Publications

9.6K

Citations

32

H-Index

YearCitations

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Richard S. Finkel, Eugenio Mercuri, Basil T. Darras,

New England Journal of Medicine

2017

2.2K

Adverse Events Associated with Testosterone Administration

Shehzad Basaria, Andrea D. Coviello, Thomas G. Travison,

New England Journal of Medicine

2010

1.5K

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

Eugenio Mercuri, Basil T. Darras, Claudia A. Chiriboga,

New England Journal of Medicine

2018

1.4K

Prevalence and Characteristics of Tinnitus among US Adults

Josef Shargorodsky, Gary C. Curhan, Wildon Farwell

The American Journal of Medicine

2010

893

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Darryl C. De Vivo, Enrico Bertini, Kathryn J. Swoboda,

Neuromuscular Disorders

2019

602

Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey

Orlando M. Gutiérrez, Wildon Farwell, Dulcie Kermah,

Osteoporosis International

2010

296

Nusinersen in later-onset spinal muscular atrophy

Basil T. Darras, Claudia A. Chiriboga, Susan T. Iannaccone,

Neurology

2019

256

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

Merit Cudkowicz, Leonard H. van den Berg, Jeremy M. Shefner,

The Lancet Neurology

2013

232

Neurofilament as a potential biomarker for spinal muscular atrophy

Basil T. Darras, Thomas O. Crawford, Richard S. Finkel,

Annals of Clinical and Translational Neurology

2019

200

The Association Between Statins and Cancer Incidence in a Veterans Population

Wildon Farwell, Richard E. Scranton, Elizabeth Lawler,

JNCI Journal of the National Cancer Institute

2008

197

Page 1